Search results
AbbVie Inc. is an American pharmaceutical company headquartered in North Chicago, Illinois. It is ranked sixth on the list of largest biomedical companies by revenue. In 2023, the company's seat in Forbes Global 2000 was 74.
Oct 28, 2021 · 200,000+. patients and healthcare providers reached through our independent healthcare grants in 2022. From drug discovery and development to ensuring our medicines are accessible and affordable, patient needs are what guide our work.
Mar 25, 2024 · NORTH CHICAGO, Ill. and NEW YORK, March 25, 2024 / PRNewswire / -- AbbVie Inc. (NYSE: ABBV) ("AbbVie") and Landos Biopharma, Inc. (NASDAQ: LABP) ("Landos") today announced a definitive agreement under which AbbVie will acquire Landos, a clinical stage biopharmaceutical company focused on the development of novel, oral therapeutics for patients ...
Nov 30, 2023 · NORTH CHICAGO, Ill., and WALTHAM, Mass., Nov. 30, 2023 / PRNewswire / -- AbbVie Inc. (NYSE: ABBV) and ImmunoGen, Inc. (NASDAQ: IMGN) today announced a definitive agreement under which AbbVie will acquire ImmunoGen, and its flagship cancer therapy ELAHERE ® (mirvetuximab soravtansine-gynx), a first-in-class antibody-drug conjugate (ADC ...
Oct 11, 2023 · NORTH CHICAGO, Ill., Oct. 11, 2023 / PRNewswire / -- AbbVie (NYSE: ABBV) today announced that its Phase 2b study evaluating upadacitinib (RINVOQ ®) in adults with non-segmental vitiligo (NSV) met the primary endpoint of percent change from baseline in the Facial Vitiligo Area Scoring Index (F-VASI) at week 24 with the 11 mg and 22 mg doses ...
Feb 12, 2024 · AbbVie expects its acquisition of ImmunoGen to be accretive to AbbVie's diluted EPS beginning in 2027 and significantly accretive over the long-term. Full-Year 2024 Outlook. AbbVie is reaffirming its previously issued 2024 full-year adjusted diluted EPS guidance range of $11.05 - $11.25.
Find the latest AbbVie Inc. (ABBV) stock quote, history, news and other vital information to help you with your stock trading and investing.
